sa���ʴ�ý������ҳ���

GelMEDIX Inc., a biotechnology company developing regenerative therapies to restore vision, and sa���ʴ�ý������ҳ���., the leader in enabling the development and supply of better treatments for patients worldwide, today announced a global partnership to access Catalent’s GMP-induced pluripotent stem cells (iPSC) and Catalent’s cell therapy manufacturing expertise and capabilities to support the development and clinical manufacturing of GelMEDIX’s iPSC-derived cell therapies to treat ocular and retinal diseases.

sa���ʴ�ý������ҳ���and S.Biomedics today announced a strategic partnership to support the development and manufacturing of TED‑A9, S.Biomedics’ allogeneic pluripotent stem-cell-derived ventral midbrain–specific dopaminergic precursor cell therapy being developed for the treatment of Parkinson’s disease.

SmartCella Holding AB (“SmartCella”), a global biopharma company developing and manufacturing, cutting-edge cell therapy approaches for difficult-to-treat diseases, and sa���ʴ�ý������ҳ���., the leader in enabling the development and supply of better treatments for patients worldwide, today announced a nonexclusive license agreement for SmartCella to use Catalent’s proprietary off-the-shelf GMP compliant induced pluripotent stem cells (iPSCs) for research, development and clinical translation of novel allogeneic stem cell-based regenerative therapies.

sa���ʴ�ý������ҳ���., a leading global contract development and manufacturing organization, today highlighted new innovations from its SMARTag® antibody-drug conjugate (ADC) technology platform.